{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-059408","form_type":"8-K","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2026-05-12T20:15:50+00:00","discovered_at":"2026-05-12T20:17:00.268352+00:00","generated_at":"2026-05-12T20:47:26.347763+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"iBio Q3: no revenue, cash $74.8M; Phase 1 clearance for IBIO-600; IBIO-610 reduces visceral fat 6.7%","bullets":["No revenue for Q3 FY2026; R&D expenses $3.3M (up $1.4M YoY); G&A $5.1M (includes $2.5M impairment of IBIO-101 intangible).","Cash, cash equivalents, and investments in debt securities $74.8M as of March 31, 2026; additional $17M from warrant exercises in Q4, extending cash runway into Q4 FY2028.","Received regulatory clearance from Australia's TGA and HREC to initiate Phase 1 trial of IBIO-600 (anti-myostatin antibody) in overweight/obese adults; first dosing expected Q2 calendar 2026.","Announced pipeline expansion into PH-HFpEF with a selective bispecific antibody blocking Activin A, GDF8, GDF11 to reduce cardiac fibrosis and vascular remodeling.","Preclinical NHP data for IBIO-610: after two doses, visceral fat reduced by 6.7%, total fat mass by 5.2% (small, not statistically powered study)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-059408","json":"https://secwatch.observer/filing/0001104659-26-059408.json","markdown":"https://secwatch.observer/filing/0001104659-26-059408.md","text":"https://secwatch.observer/filing/0001104659-26-059408.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000110465926059408/0001104659-26-059408-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000110465926059408/ibio-20260512x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T20:47:26.347763+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"89c8c7758aba96edf84d1fd12a58163a03ec49a7","claim":"iBio, Inc. reported financial results for third quarter ended Mar. 31, 2026.","evidence_excerpt":"On May 12, 2026, iBio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420720/000110465926059408/0001104659-26-059408-index.htm","confidence":0.4,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended Mar. 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}